UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 34, 2022

Zymeworks Inc.

(Exact name of registrant as specified in its charter)

British Columbia, Canada

001-38068

98-1398788

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Suite 800, 114 East 4th Avenue, Vancouver, British Columbia,

Canada

V5T 1G4

(Address of principal executive offices)

(Zip Code)

(604) 678-1388

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Shares, no par value per share

ZYME

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 7.01 ~~REGULATION~~Regulation FD ~~DISCLOSURE~~Disclosure

On October 34, 2022, Zymeworks Inc. (the “Company” or “Zymeworks”) issued a press release ~~announcing~~reminding ~~that~~its ~~management~~securityholders ~~will~~of ~~participate~~the indeadline to vote for a resolution to approve a series of transactions, including a corporate redomicile, at the ~~following~~Company’s upcoming ~~investor~~special ~~conferences:~~meeting of securityholders to be held on October 7, 2022.

•On ~~Stifel~~October 4, 2022, ~~Healthcare~~the ~~Conference.~~Company ~~Zymeworks’~~filed ~~management~~a ~~will~~press ~~participate~~release inregarding ~~one-~~the deadline for voting with the Canadian securities regulatory authorities on~~-one~~ ~~meetings~~the System for Electronic Document Analysis and ~~present~~Retrieval onat ~~November~~www.sedar.com ~~15th~~(“SEDAR”). -A ~~16th~~copy inof ~~New~~this ~~York,~~press NYrelease is attached as Exhibit 99.1 hereto.

•The ~~Jefferies~~information ~~London~~under ~~Healthcare~~this ~~Conference~~Item 7.01 ~~Zymeworks’~~of ~~management~~this ~~will~~Current ~~participate~~Report inon ~~one~~Form 8-~~on-one~~K ~~meetings~~and Exhibit 99.1 attached hereto are being furnished and ~~present~~shall onnot ~~November~~be ~~15th~~deemed -“filed” ~~17th~~for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in ~~London~~any filing under the Exchange Act or the Securities Act of 1933, ~~United~~as ~~Kingdom~~amended (the “Securities Act”), regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

~~This~~Important ~~press~~Information ~~release~~for ~~also~~Investors ~~announced~~and ~~that Zymeworks will present an update on its preclinical research programs at an Early R&D day on October 20th, 2022, in New York, NY.~~Securityholders

OnThis ~~October 3~~communication is not intended to and does not constitute an offer to sell, ~~2022~~buy or exchange or the solicitation of an offer to sell, buy or exchange any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, purchase, or exchange of securities or solicitation of any vote or approval in any jurisdiction in contravention of applicable law. In connection with the proposed redomicile (the “Redomicile”), Zymeworks ~~filed~~has ~~this~~caused ~~press~~its ~~release~~subsidiary Zymeworks Delaware Inc., a Delaware corporation (“New Zymeworks”), to file a registration statement on Form S-4, which includes New Zymeworks’ prospectus as well as Zymeworks’ proxy statement (the “Proxy Statement/Prospectus”), with the U.S. Securities and Exchange Commission (the “SEC”) and the appropriate Canadian securities regulatory authorities. Zymeworks has mailed the Proxy Statement/Prospectus to its shareholders and holders of its warrants and outstanding equity awards in connection with the proposed Redomicile. INVESTORS AND SECURITYHOLDERS OF ZYMEWORKS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ZYMEWORKS, NEW ZYMEWORKS, THE REDOMICILE, AND RELATED MATTERS. Investors and securityholders are able to obtain free copies of the Proxy Statement/Prospectus and other documents filed with the SEC by Zymeworks or New Zymeworks through the website maintained by the SEC at www.sec.gov (“EDGAR”). Investors and securityholders are also able to obtain free copies of the Proxy Statement/Prospectus and other documents filed with Canadian securities regulatory authorities by Zymeworks, through the website maintained by the Canadian Securities Administrators on SEDAR. In addition, investors and securityholders are able to obtain free copies of the ~~System~~documents ~~for~~filed ~~Electronic~~with ~~Document~~the ~~Analysis~~SEC and ~~Retrieval~~Canadian securities regulatory authorities on Zymeworks’ website at www.~~sedar~~zymeworks.com or by contacting Zymeworks’ corporate secretary.

AParticipants ~~copy~~in ofthe ~~this press release is attached as Exhibit 99.1 hereto.~~Solicitation

~~The~~Zymeworks ~~information~~and ~~under~~certain ~~this~~of ~~Item~~its ~~7.01~~directors, ofexecutive ~~this~~officers ~~Current~~and ~~Report~~employees onmay ~~Form~~be ~~8-K~~considered ~~and~~participants ~~Exhibit~~in 99the solicitation of proxies in connection with the proposed Redomicile.1 ~~attached~~Information ~~hereto~~regarding ~~are~~the ~~being~~persons ~~furnished~~who ~~and~~may, ~~shall~~under ~~not~~the rules of the SEC, be deemed ~~“filed”~~participants ~~for~~in the ~~purposes~~solicitation of ~~Section 18~~the securityholders of Zymeworks in connection with the ~~Securities~~proposed ~~Exchange~~Redomicile, ~~Act~~including a description of ~~1934~~their ~~(the~~respective ~~“Exchange~~direct ~~Act”)~~or indirect interests, by security holdings or otherwise, ~~subject~~is toincluded in the ~~liability~~Proxy ofStatement/Prospectus ~~that~~described ~~section,~~above. ~~nor~~Additional ~~shall such~~ information beregarding ~~deemed~~Zymeworks’ ~~incorporated~~directors byand ~~reference~~executive inofficers ~~any~~is ~~filing~~also ~~under~~included ~~the~~in ~~Exchange~~Zymeworks’ ~~Act~~Amendment orNo. 1 to the ~~Securities~~Annual ~~Act~~Report ofon ~~1933~~Form 10-K/A, aswhich ~~amended,~~was ~~regardless~~filed ofwith the ~~general~~SEC ~~incorporation~~and ~~language~~Canadian ofsecurities ~~such~~regulatory ~~filing,~~authorities ~~except~~on asMay 2, ~~shall~~2022. beThis ~~expressly~~document ~~set~~is ~~forth~~available byfree ~~specific~~of ~~reference~~charge inas ~~such~~described ~~filing~~above.

Cautionary Note Regarding Forward-Looking Statements

This communication includes “forward-looking statements” or information within the meaning of applicable securities legislation, including Section 27A of the Securities Act, and Section 21E of the Exchange Act. Forward-looking statements in this communication include, but are not limited to, statements that relate to expected benefits of the Redomicile; opportunities to enhance long-term value for securityholders as a U.S. corporation; opportunities to expand the institutional investor base; ability to commercialize its products in the United States; and other information that is not historical information. When used herein, words such as “intention”, “subject to”, believes”, “propose”, “will”, “future”, “may”, “anticipates”, “pending”, “plans”, “potential”, “expect” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: the impact of the COVID-19 pandemic on Zymeworks’ business, research and clinical

development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf, may be more severe and more prolonged than currently anticipated; the ability to receive, in a timely manner and on satisfactory terms, the required securityholder, stock exchange and court approvals; the anticipated last day of trading Zymeworks common shares on the New York Stock Exchange and the anticipated trading of shares of common stock of New Zymeworks following the completion of the Redomicile; and assumptions in corporate guidance. Risks and uncertainties include, but are not limited to: the anticipated benefits of the Redomicile may not be achieved; the receipt of securityholder, stock exchange and court approvals and satisfaction of other conditions in connection with the Redomicile may not be obtained; the anticipated tax consequences and impact of the Redomicile to Zymeworks securityholders, Zymeworks and New Zymeworks may not materialize; risks relating to New Zymeworks following the Redomicile, including triggering provisions in certain agreements that require consent or may result in termination; publicity resulting from the Redomicile and impacts to the company’s business and share price; risks that the description of the transactions in external communications may not properly reflect the underlying legal and tax principles of the Redomicile; the benefits of being a U.S. corporation on efforts to commercialize zanidatamab may not be realized; changes in or interpretation of laws or regulations may prevent the realization of anticipated benefits from the Redomicile; risks associated with existing or potential lawsuits and regulatory actions; the impact of disputes arising with partners; and other risks and uncertainties as described in Zymeworks’ Annual Report on Form 10-K, as amended, and Quarterly Report on Form 10-Q and as described from time to time in Zymeworks’ other periodic filings as filed on SEDAR and EDGAR.

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

ExhibitNo.		Description
Exhibit No.		Description
99.1		Press Release dated October 34, 2022.
104		Cover Page Interactive Data File (embedded as Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ZYMEWORKS INC.

(Registrant)

Date: October 3, 2022

/s/ Neil A. Klompas

Date: October 4, 2022

/s/ Neil A. Klompas

Neil A. Klompas

President and Chief Operating Officer

Filing Compare · Zymeworks BC Inc.